15 February 2019 - Based on new analyses of published results of the ODYSSEY Outcomes trial, alirocumab would meet cost-effectiveness thresholds if priced between $2,300 and $4,000 per year, depending on population.

The ICER today released a final new evidence update for alirocumab (Praluent, Regeneron/Sanofi), an injectable PCSK9 inhibitor used for the treatment of high cholesterol in certain patient populations. This new evidence update is based on further analysis of results from the ODYSSEY Outcomes trial, which have now undergone peer review and were published in the New England Journal of Medicine on November 7, 2018.

Based on these new analyses, ICER is revising its value-based price benchmark ranges for alirocumab to $2,300-$3,500 per year if used to treat all patients who meet ODYSSEY trial eligibility criteria, and $2,700-$4,000 per year if only used to treat higher-risk patients with LDL cholesterol ≥ 100 mg/dL despite intensive statin therapy. ICER’s value-based price benchmarks suggest a price range, net of any discounts and rebates, that aligns fairly with the treatment’s added benefits for patients and the health care system. The ranges reflect commonly cited cost-effectiveness thresholds of between $100,000 and $150,000 per quality-adjusted life year gained.

Read ICER announcement